Current treatment strategies for patients with Hodgkin’s lymphoma and HIV infection
Authors:
- Pia HartmannPHPia Hartmann
- Ute RehwaldURUte Rehwald
- Bernd SalzbergerBSBernd Salzberger
- Caspar FranzenCFCaspar Franzen
- Volker DiehlVDVolker Diehl
- 1 June 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 4 (3) , 401-410
Abstract
Hodgkin's lymphoma is the most common non-AIDS-defining tumor diagnosed in HIV-infected patients. Although the introduction of highly active antiretroviral therapy (HAART) led to a decreased incidence of several malignancies among HIV-infected patients, the incidence of HIV-associated Hodgkin's lymphoma (HIV-HL) has been persistent in recent years. Its unusually aggressive tumor behavior includes a higher frequency of unfavorable histologic subtypes, high stage and extranodal involvement by the time of presentation and poor therapeutic outcome, in comparison with Hodgkin's lymphoma outside the HIV setting. Treatment of HIV-HL is challenging considering the underlying immunodeficiency caused by HIV itself and may increase the risk of opportunistic infections by inducing further immunosuppression. To address this delicate vulnerability of the HIV-infected host, tailored regimens, which are less aggressive than standard regimens for HIV-negative hosts, have been applied to achieve tumor control. The introduction of HAART has opened a new perspective in the treatment of HIV-associated malignancies. The improved control of HIV infection and the subsequently improved survival rates of HIV-infected patients has changed the goal from tumor control to cure and new treatment approaches with more potent regimens need to be evaluated to improve survival and quality of life in HIV-HL.Keywords
This publication has 35 references indexed in Scilit:
- Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapyAIDS, 2003
- Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapyBlood, 2001
- Changing Incidence and Survival in Patients with AIDS-Related Non-Hodgkin's Lymphomas in the Era of Highly Active Antiretroviral Therapy (HAART)Leukemia & Lymphoma, 2001
- Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: A comparative studyHuman Pathology, 1996
- Annotation AIDS‐RELATED LYMPHOMAS: FROM PATHOGENESIS TO PATHOLOGYBritish Journal of Haematology, 1995
- Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression.Journal of Clinical Oncology, 1993
- Clinically unsuspected Hodgkin disease presenting initially in the bone marrow of patients infected with the human immunodeficiency virusCancer, 1993
- IDENTIFICATION OF EBV-DNA IN TUMOUR CELLS OF AIDS-RELATED LYMPHOMAS BY IN-SITU HYBRIDISATIONThe Lancet, 1989
- AIDS-related lymphoid neoplasia. The memorial hospital experienceCancer, 1988
- HIV-Related Hematological Neoplasias in France1988